Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGXJT Combining With ICIs in Bone Metastatic NSCLC Patients
NCT05378334Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jun 2022
- Primary completion
- Sep 2027
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Randomised, double-blind trial of HuGuXiaoJiTang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Disease Control Rate up to 120 months. Started Jun 2022; status: recruiting.
02
Drugs
HuGuXiaoJiTang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05378334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378334.